Although drug rebates have been an area of high focus for reform, the Trump Administration decided yesterday to withdraw its plan to eliminate rebates from government-sponsored drug plans. Read more
Kirollos S. Hanna, PharmD, BCPS, BCOP
Oral oncolytics, or oral chemotherapies, have significantly impacted the treatment of cancer. They enable patients to conveniently manage treatment in their homes. Despite the rapid growth, therapeutic advances, novel mechanisms of actions, and improved outcomes associated with these agents, the dispensing process remains inadequate. As a result of rising drug costs and healthcare expenditures, payers have forced a “medically disintegrated” model of dispensing, limiting patients and practices to fill prescriptions through external mail-order pharmacies. Read more.
A recent study found that patients receiving Daratumumab treatment may benefit from an alternative dosing technique of subcutaneous (SQ) administration vs. the traditional IV infusion. Clinicians should be aware of advancing developments that have the potential to reduce the treatment burden and positively impact a patient’s quality of life. READ MORE HERE